# MAP3K7

## Overview
MAP3K7, also known as Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), is a gene that encodes the serine/threonine kinase protein TAK1. This kinase is a critical mediator in various signaling pathways, including those triggered by cytokines and growth factors, which are essential for immune responses, cell growth, and survival (Micale2020Insights). TAK1 activates both the NF-ÎºB and MAPK pathways, playing a pivotal role in inflammatory and stress responses (Zehavi2015MiR-377). The protein itself is characterized by a kinase domain essential for its enzymatic activity and a coiled-coil domain that facilitates interactions with other proteins such as TAB2, which are crucial for its activation and function (Wade2016Mutations). Mutations and dysregulation of MAP3K7 have been implicated in various diseases, including cancer and developmental disorders, highlighting its importance in health and disease (Micale2020Insights; Wade2016Mutations).

## Structure
The molecular structure of the protein encoded by the MAP3K7 gene, known as TAK1, includes several distinct domains crucial for its function. The N-terminal kinase domain of TAK1 is well-characterized, with a crystal structure available that highlights a tightly constrained beta-hairpin turn essential for ordering the active site of the kinase domain (Wade2016Mutations). This domain is critical for the kinase's enzymatic activity. 

The C-terminal region of TAK1 features a coiled-coil domain, which is involved in protein-protein interactions, specifically with TAB2, and may also contribute to homodimerization (Wade2016Mutations). However, structural data for the linker region and the complete C-terminus are not available, indicating a gap in the full structural understanding of TAK1.

Regarding post-translational modifications, TAK1 is subject to autophosphorylation, which is crucial for its activation and function in signaling pathways (Wade2016Mutations). The protein also interacts with ubiquitin chains, which are important for its activation; however, specific details on ubiquitination sites or other modifications like phosphorylation are not detailed in the provided excerpts.

The available information does not cover the primary, secondary, tertiary, or quaternary structures in detail, nor does it provide comprehensive insights into splice variant isoforms or other potential post-translational modifications beyond autophosphorylation.

## Function
MAP3K7, also known as Transforming growth factor beta-activated kinase 1 (TAK1), is a serine/threonine kinase that plays a pivotal role in various cellular processes. It is encoded by the MAP3K7 gene located on chromosome 6q15 and is activated by multiple extracellular stimuli including growth factors such as TGF-Î², interleukin-1 (IL-1), tumor necrosis factors Î± (TNFÎ±), and Toll-like receptors (Micale2020Insights). TAK1 is essential for the activation of downstream signaling pathways such as nuclear factor Îº-B (NF-ÎºB) and mitogen-activated protein kinase (MAPK), which are crucial for inflammatory responses and cell survival (Zehavi2015MiR-377).

The protein interacts with TAK1 binding proteins (TABs), particularly TAB1, which is necessary for its activation and function. This interaction is critical for the TGFÎ² signal transduction, influencing the transcriptional regulation of target genes within the MAPK-p38 pathway and impacting cellular behaviors such as proliferation, migration, apoptosis, and differentiation (Micale2020Insights). Additionally, TAK1 plays a significant role in the regulation of the NF-kB and MAPK signaling pathways, orchestrating a wide array of cellular functions including the maintenance of extracellular matrix (ECM) homeostasis and mediating fibrotic responses (Micale2020Insights).

Mutations in MAP3K7 can lead to altered connective tissue structure and function, demonstrating the gene's crucial role in maintaining structural integrity and function of various cellular components (Micale2020Insights). Thus, the normal activity of TAK1 is vital for various physiological processes and organismal outcomes, underscoring its importance in human health and disease.

## Clinical Significance
MAP3K7, implicated in various diseases, plays a significant role in the pathogenesis of hepatocellular carcinoma (HCC). Elevated MAP3K7 expression correlates with poor survival rates in HCC patients, suggesting its potential as a therapeutic target. The gene's interaction with the mTOR signaling pathway further emphasizes its role in promoting tumor malignancy (Cheng2019The).

Mutations in MAP3K7 are also linked to skeletal dysplasias such as frontometaphyseal dysplasia (FMD) and cardiospondylocarpofacial syndrome (CSCFS). In FMD, specific mutations like the recurrent missense mutation p.Pro485Leu lead to severe phenotypes, affecting bone modeling and joint function (Costantini2018Expansion; Wade2016Mutations). Similarly, CSCFS is associated with various MAP3K7 mutations that result in growth retardation, distinctive facial features, and skeletal anomalies, highlighting the gene's crucial role in bone morphogenesis and development (Micale2020Insights; Le2016Heterozygous).

These findings underscore the clinical significance of MAP3K7 in both oncological and developmental disorders, providing insights into its dual role in promoting cancer progression and contributing to congenital malformations.

## Interactions
MAP3K7, also known as TAK1, interacts with a variety of adaptor and effector proteins that modulate its function in multiple signaling pathways. One of the key interactions is with TAB2 and TAB3, which are crucial for the activation of TAK1 in response to inflammatory cytokines and other stimuli. TAB2 and TAB3 bind directly to the polyubiquitin chains linked by lysine 63, which are essential for TAK1 activation (Zhang2024Regulation). Additionally, TAK1 forms a complex with TRAF6, facilitated by TAB2, which is vital for the downstream activation of NF-ÎºB and MAPK pathways (Takaesu2000TAB2; Wang2001TAK1).

Another significant interaction is with TRIM31, an E3 ubiquitin ligase that targets MAP3K7 for proteasomal degradation. This interaction is mediated by the amino-terminal 300 amino acids of MAP3K7 and is crucial for regulating the levels of MAP3K7 in the TGF-Î²1 signaling pathway (Zhang2021The). Furthermore, MAP3K7 interacts with TAB1, which binds directly to the N-terminal kinase domain of TAK1, playing a role in its activation and autophosphorylation (Zhang2024Regulation).

These interactions highlight the complex regulatory mechanisms that control MAP3K7 activity and stability, impacting various cellular processes including immune responses and cell growth.


## References


[1. (Takaesu2000TAB2) Giichi Takaesu, Satoshi Kishida, Atsushi Hiyama, Kyoko Yamaguchi, Hiroshi Shibuya, Kenji Irie, Jun Ninomiya-Tsuji, and Kunihiro Matsumoto. Tab2, a novel adaptor protein, mediates activation of tak1 mapkkk by linking tak1 to traf6 in the il-1 signal transduction pathway. Molecular Cell, 5(4):649â658, April 2000. URL: http://dx.doi.org/10.1016/s1097-2765(00)80244-0, doi:10.1016/s1097-2765(00)80244-0. (488 citations) 10.1016/s1097-2765(00)80244-0](https://doi.org/10.1016/s1097-2765(00)80244-0)

[2. (Zhang2024Regulation) Jie Zhang, Lei Cao, Lijuan Lyu, Wenqian Qi, Wei Yang, Ruiqing Ren, Chunyu Kao, Yun Zhang, Cheng Zhang, and Meng Zhang. Regulation of takâtab complex activation through ubiquitylation. Frontiers in Bioscience-Landmark, 29(5):169, April 2024. URL: http://dx.doi.org/10.31083/j.fbl2905169, doi:10.31083/j.fbl2905169. (0 citations) 10.31083/j.fbl2905169](https://doi.org/10.31083/j.fbl2905169)

[3. (Zhang2021The) Jie Zhang, Lei Cao, Xiaohong Wang, Qian Li, Meng Zhang, Cheng Cheng, Liwen Yu, Fei Xue, Wenhai Sui, Shangwen Sun, Na li, Peili Bu, Bingyu Liu, Fei Gao, Junhui Zhen, Guohai Su, Cheng Zhang, Chengjiang Gao, Meng Zhang, and Yun Zhang. The e3 ubiquitin ligase trim31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of map3k7 in the tgf-Î²1 signaling pathway. Cell Death &amp; Differentiation, 29(3):556â567, September 2021. URL: http://dx.doi.org/10.1038/s41418-021-00874-0, doi:10.1038/s41418-021-00874-0. (19 citations) 10.1038/s41418-021-00874-0](https://doi.org/10.1038/s41418-021-00874-0)

[4. (Le2016Heterozygous) Carine Le Goff, Curtis Rogers, Wilfried Le Goff, Graziella Pinto, Damien Bonnet, Maya Chrabieh, Olivier Alibeu, Patrick Nistchke, Arnold Munnich, Capucine Picard, and ValÃ©rie Cormier-Daire. Heterozygous mutations in map3k7 , encoding tgf-Î²-activated kinase 1, cause cardiospondylocarpofacial syndrome. The American Journal of Human Genetics, 99(2):407â413, August 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.06.005, doi:10.1016/j.ajhg.2016.06.005. (41 citations) 10.1016/j.ajhg.2016.06.005](https://doi.org/10.1016/j.ajhg.2016.06.005)

[5. (Zehavi2015MiR-377) Liron Zehavi, Hagit Schayek, Jasmine Jacob-Hirsch, Yechezkel Sidi, Raya Leibowitz-Amit, and Dror Avni. Mir-377 targets e2f3 and alters the nf-kb signaling pathway through map3k7 in malignant melanoma. Molecular Cancer, March 2015. URL: http://dx.doi.org/10.1186/s12943-015-0338-9, doi:10.1186/s12943-015-0338-9. (86 citations) 10.1186/s12943-015-0338-9](https://doi.org/10.1186/s12943-015-0338-9)

[6. (Wade2016Mutations) Emma M. Wade, Philip B. Daniel, Zandra A. Jenkins, Aideen McInerney-Leo, Paul Leo, Tim Morgan, Marie Claude Addor, Lesley C. AdÃ¨s, Debora Bertola, Axel Bohring, Erin Carter, Tae-Joon Cho, Hans-Christoph Duba, Elaine Fletcher, Chong A. Kim, Deborah Krakow, Eva Morava, Teresa Neuhann, Andrea Superti-Furga, Irma Veenstra-Knol, Dagmar Wieczorek, Louise C. Wilson, Raoul C.M. Hennekam, Andrew J. Sutherland-Smith, Tim M. Strom, Andrew O.M. Wilkie, Matthew A. Brown, Emma L. Duncan, David M. Markie, and Stephen P. Robertson. Mutations in map3k7 that alter the activity of the tak1 signaling complex cause frontometaphyseal dysplasia. The American Journal of Human Genetics, 99(2):392â406, August 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.05.024, doi:10.1016/j.ajhg.2016.05.024. (71 citations) 10.1016/j.ajhg.2016.05.024](https://doi.org/10.1016/j.ajhg.2016.05.024)

[7. (Cheng2019The) Jin-Shiung Cheng, Wei-Lun Tsai, Pei-Feng Liu, Yih-Gang Goan, Chih-Wen Lin, Ho-Hsing Tseng, Cheng-Hsin Lee, and Chih-Wen Shu. The map3k7-mtor axis promotes the proliferation and malignancy of hepatocellular carcinoma cells. Frontiers in Oncology, June 2019. URL: http://dx.doi.org/10.3389/fonc.2019.00474, doi:10.3389/fonc.2019.00474. (21 citations) 10.3389/fonc.2019.00474](https://doi.org/10.3389/fonc.2019.00474)

[8. (Costantini2018Expansion) Alice Costantini, Carina Wallgren-Pettersson, and Outi MÃ¤kitie. Expansion of the clinical spectrum of frontometaphyseal dysplasia 2 caused by the recurrent mutation p.pro485leu in map3k7. European Journal of Medical Genetics, 61(10):612â615, October 2018. URL: http://dx.doi.org/10.1016/j.ejmg.2018.04.004, doi:10.1016/j.ejmg.2018.04.004. (12 citations) 10.1016/j.ejmg.2018.04.004](https://doi.org/10.1016/j.ejmg.2018.04.004)

[9. (Micale2020Insights) Lucia Micale, Silvia Morlino, Tommaso Biagini, Annalucia Carbone, Carmela Fusco, Marco Ritelli, Vincenzo Giambra, Nicoletta Zoppi, Grazia Nardella, Angelantonio Notarangelo, Annalisa Schirizzi, Gianluigi Mazzoccoli, Paola Grammatico, Emma M. Wade, Tommaso Mazza, Marina Colombi, and Marco Castori. Insights into the molecular pathogenesis of cardiospondylocarpofacial syndrome: map3k7 c.737-7a &gt; g variant alters the tgfÎ²-mediated Î±-sma cytoskeleton assembly and autophagy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1866(6):165742, June 2020. URL: http://dx.doi.org/10.1016/j.bbadis.2020.165742, doi:10.1016/j.bbadis.2020.165742. (11 citations) 10.1016/j.bbadis.2020.165742](https://doi.org/10.1016/j.bbadis.2020.165742)

[10. (Wang2001TAK1) Chen Wang, Li Deng, Mei Hong, Giridhar R. Akkaraju, Jun-ichiro Inoue, and Zhijian J. Chen. Tak1 is a ubiquitin-dependent kinase of mkk and ikk. Nature, 412(6844):346â351, July 2001. URL: http://dx.doi.org/10.1038/35085597, doi:10.1038/35085597. (1642 citations) 10.1038/35085597](https://doi.org/10.1038/35085597)